login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
KRYSTAL BIOTECH INC (KRYS) Stock News
USA
- NASDAQ:KRYS -
US5011471027
-
Common Stock
155
USD
+0.62 (+0.4%)
Last: 9/17/2025, 2:32:40 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
KRYS Latest News, Press Relases and Analysis
All
Press Releases
2 days ago - By: Benzinga
FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin
2 days ago - By: Krystal Biotech, Inc.
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
14 days ago - By: Zacks Investment Research
- Mentions:
ALKS
Krystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue?
15 days ago - By: Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
15 days ago - By: Krystal Biotech, Inc.
Krystal Biotech to Present at Cantor Global Healthcare Conference 2025
a month ago - By: The Motley Fool
Krystal (KRYS) Q2 Profit Jumps 143%
a month ago - By: Krystal Biotech, Inc.
Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer
a month ago - By: Yahoo Finance
Krystal Biotech price target lowered to $182 from $192 at BofA
a month ago - By: Zacks Investment Research
- Mentions:
CRMD
IMCR
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook
a month ago - By: Krystal Biotech, Inc.
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results
2 months ago - By: Zacks Investment Research
- Mentions:
TNGX
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2 months ago - By: Krystal Biotech, Inc.
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
2 months ago - By: Krystal Biotech, Inc.
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
2 months ago - By: Krystal Biotech, Inc.
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
4 months ago - By: Zacks Investment Research
Implied Volatility Surging for Krystal Biotech Stock Options
3 months ago - By: The Motley Fool
- Mentions:
TMDX
PODD
OPCH
BEAM
...
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
3 months ago - By: Krystal Biotech, Inc.
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
3 months ago - By: Zacks Investment Research
- Mentions:
BIIB
Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report?
4 months ago - By: Krystal Biotech, Inc.
Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference
Please enable JavaScript to continue using this application.